Regulation of mast cell responses in health and disease

Critical Reviews in Immunology

Volumn 31, Issue 6, 2011, Pages 475-530

  Gilfillan, Alasdair M ^a   Beaven, Michael A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Allergies; Autoimmune diseases; FceRI; GPCRs; Immunity; KIT; Mast cells; Signaling; TLR ST2 NOD like receptors

Indexed keywords

ADENOSINE RECEPTOR; ANGIOPOIETIN 1; CELL RECEPTOR; CHEMOKINE RECEPTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR ANTAGONIST; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR ALPHA; JANUS KINASE; LEUKOTRIENE C4; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOLIPASE C GAMMA2; PROSTAGLANDIN D2; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALLERGIC RHINITIS; ANGIOGENESIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BASOPHIL; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; BULLOUS PEMPHIGOID; CALCIUM SIGNALING; CARCINOGENESIS; CD34 SELECTION; CELL ACTIVATION; CELL GROWTH; CELL HYPERPLASIA; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTAXIS; CLINICAL FEATURE; CROHN DISEASE; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME REGULATION; EXOCYTOSIS; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LISTERIA MONOCYTOGENES; MAST CELL; MAST CELL DEGRANULATION; MULTIPLE SCLEROSIS; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PRURITUS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; TH2 CELL; TUMOR GROWTH; UPREGULATION; URTICARIA; VASODILATATION; WOUND HEALING;

EID: 84856606100     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v31.i6.30     Document Type: Article

References (455)

1. Crivellato E, Ribatti D. The mast cell: an evolutionary perspective. Biol Rev Camb Philos Soc. 2010;85:347-60.
2. Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system. Immunobiology. 2008;213:251-60.
3. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol. 1999;11:53-59.
4. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10:440-452.
5. Galinsky DS, Nechushtan H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol. 2008;68:115-30.
6. Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta. 2010;1822:2-8.
7. Saito H. Role of mast cell proteases in tissue remodeling. Chem Immunol Allergy. 2005;87:80-84.
8. Norrby K. In vivo models of angiogenesis. J Cell Mol Med. 2006;10:588-612.
9. Noli C, Miolo A. The mast cell in wound healing. Vet Dermatol. 2001;12:303-13.
10. Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol. 2011;716:270-288.
11. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009;1796:19-26.
12. Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol. 2009;39:11-25.
13. Moon TC, St Laurent CD, Morris KE, Marcet C, Yoshimura T, Sekar Y, Befus AD. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 2010;3:111-28.
14. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 2010;40:1843-51.
15. Collington SJ, Williams TJ, Weller CL. Mechanisms underlying the localisation of mast cells in tissues. Trends Immunol. 2011;32:478-85.
16. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218-30.
17. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol. 2007;19:31-38.
18. Qiao H, Andrade MV, Lisboa FA, Morgan K, Beaven MA. FcεRI and Toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood. 2006;107:610-618.
19. Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha-Melo JR, Beaven MA. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol. 2011;41:760-72.
20. Abramson J, Pecht I. Regulation of the mast cell response to the type 1 Fcε receptor. Immunol Rev. 2007;217:231-54.
21. Karra L, Levi-Schaffer F. Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv Exp Med Biol. 2011;716:143-59.
22. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033-79.
23. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131-40.
24. Iwaki S, Tkaczyk C, Satterthwaite AB, Halcomb K, Beaven MA, Metcalfe DD, Gilfillan AM. Btk plays a crucial role in the amplification of FcεRI-mediated mast cell activation by Kit. J Biol Chem. 2005;280:40261-70.
25. McNeil HP, Adachi R, Stevens RL. Mast cellrestricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem. 2007;282:20785-89.
26. Stevens RL, Adachi R. Protease-proteoglycan complexes of mouse and human mast cells and importance of their b-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev. 2007;217:155-67.
27. Schwartz LB. Tryptase: a clinical indicator of mast cell-dependent events. Allergy Proc. 1994;15:119-23.
28. Jones BL, Kearns GL. Histamine: new thoughts about a familiar mediator. Clin Pharmacol Ther. 2011;89:189-97.
29. Bongers G, de Esch I, Leurs R. Molecular pharmacology of the four histamine receptors. Adv Exp Med Biol. 2011;709:11-19.
30. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003;305:1212-21.
31. Leurs R, Vischer HF, Wijtmans M, de Esch IJ. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci. 2011;32:250-257.
32. Inoue H, Nagata N, Koshihara Y. Participation of serotonin in capsaicin-induced mouse ear edema. Jpn J Pharmacol. 1995;69:61-68.
33. Krop M, Özünal ZG, Chai W, de Vries R., Fekkes D, Bouhuizen AM, Garrelds IM, Danser AHJ. Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release. Eur J Pharmacol. 2010;640:185-89.
34. Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol. 2007;119:498-99.
35. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol. 2000;85:521-44.
36. Enomoto U, Kusakabe H, Matsumura T, Kuno T, Tamai H, Kiyokane K. Diffuse cutaneous mastocytosis responding to cyproheptadine. Clin Exp Dermatol. 1999;24:16-18.
37. Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Tanghellini V, Rundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290-1298.
38. Irani AM, Schwartz LB. Human mast cell heterogeneity. Allergy Proc. 1994;15:303-8.
39. Knight PA, Wright SH, Lawrence CE, Paterson YY, Miller HR. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med. 2000;192:1849-56.
40. McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grencis RK. Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl Acad Sci U S A. 2003;100:7761-66.
41. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, Tsai M, Galli SJ. Mast cells can enhance resistance to snake and honeybee venoms. Science. 2006;313:526-30.
42. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev. 2007;217:141-54.
43. Boyce JA. Eicosanoid mediators of mast cells: receptors, regulation of synthesis, and pathobiologic implications. Chem Immunol Allergy. 2005;87:59-79.
44. Boyce JA. Eicosanoids in asthma, allergic inflammation, and host defense. Curr Mol Med. 2008;8:335-49.
45. Swindle EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in mast celldependent inflammatory processes. Immunol Rev. 2007;217:186-205.
46. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, FcεRI, on human mast cells: up-regulation by IFN-a. J Immunol. 2000;164:4332-39.
47. Okayama Y, Hagamann DD, Metcalfe DD. A comparison of mediators released or generated by IFN-a-treated human mast cells following aggregation of FcεRI or FcεRI. J Immunol. 2001;166:4705-12.
48. Okayama Y. Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors. Chem Immunol Allergy. 2005;87:101-10.
49. Katsanos GS, Anogeianaki A, Orso C, Tetè S, Salini V, Antinolfi PL, Sabatino G. Mast cells and chemokines. J Biol Regul Homeost Agents. 2008;22:145-51.
50. Moiseeva EP, Bradding P. Mast cells in lung inflammation. Adv Exp Med Biol. 2011;716:235-69.
51. Tsai M, Grimbaldeston M, Galli SJ. Mast cells and immunoregulation/immunomodulation. Adv Exp Med Biol. 2011;716:186-211.
52. Shelburne CP, Abraham SN. The mast cell in innate and adaptive immunity. Adv Exp Med Biol. 2011;716:162-85.
53. Leonard WJ. TSLP: finally in the limelight. Nat Immunol. 2002;3:605-7.
54. Ziegler SF, Liu Y-J. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat Immunol. 2006;7:709-14.
55. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, Ziegler SF, Sarfati M, Delespesse G. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253-58.
56. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation in an asthma model. J Exp Med. 2005;202:829-39.
57. Okayama Y, Okumura S, Sagara H, Yuki K, Sasaki T, Watanabe N, Fueki M, Sugiyama K, Takeda K, Fukuda T, Saito H, Ra C. FcεRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J. 2009;34:425-35.
58. Li YL, Li HJ, Ji F, Zhang X, Wang R, Hao JQ, Bi WX, Dong L. Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. J Asthma. 2010;47:117-23.
59. Kashyap M, Rochman Y, Spolski R, Samsel L, Leonard WJ. Thymic stromal lymphopoietin is produced by dendritic cells. J Immunol. 2011;187:1207-11.
60. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101:13607-12.
61. Morrey C, Brazin J, Seyedi N, Corti F, Silver RB, Levi R. Interaction between sensory C-fibers and cardiac mast cells in ischemia/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction. J Pharmacol Exp Ther. 2010;335:76-84.
62. Veerappan A, Reid AC, Estephan R, O'Connor N, Thadani-Mulero M, Salazar-Rodriguez M, Levi R, Silver RB. Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction. Proc Natl Acad Sci U S A. 2008;105:1315-20.
63. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol. 2008;19:2254-61.
64. Company C, Piqueras L, Naim Abu NY, Escudero P, Blanes JI, Jose PJ, Morcillo EJ, Sanz MJ. Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo. Cardiovasc Res. 2011;i92:48-56.
65. Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol. 2007;7:365-78.
66. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol. 2006;117:1214-25.
67. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009;228:149-69.
68. Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. 2009;124:639-46.
69. Tkaczyk C, Okayama Y, Metcalfe DD, Gilfillan AM. Fcg receptors on mast cells: activatory and inhibitory regulation of mediator release. Int Arch Allergy Immunol. 2004;133:305-15.
70. Kuehn HS, Radinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, Metcalfe DD, Gilfillan AM. Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci. 2010;123:2576-85.
71. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2:773-86.
72. Kashiwakura J, Otani IM, Kawakami T. Monomeric IgE and mast cell development, survival and function. Adv Exp Med Biol. 2011;716:29-46.
73. Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, Liu F-T, Galli SJ, Kawakami T. Regulation of mast cell survival by IgE. Immunity. 2001;14:791-800.
74. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, Krystal G. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001;14:801-11.
75. Kitaura J, Kinoshita T, Matsumoto M, Chung S, Kawakami Y, Leitges M, Wu D, Lowell CA, Kawakami T. IgE-and IgE1Ag-mediated mast cell migration in an autocrine/paracrine fashion. Blood. 2005;105:3222-29.
76. Matsuda K, Piliponsky AM, Iikura M, Nakae S, Wang EW, Dutta SM, Kawakami T, Tsai M, Galli SJ. Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response. J Allergy Clin Immunol. 2005;116:1357-63.
77. Cruse G, Kaur D, Yang W, Duffy SM, Brightling CE, Bradding P. Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J. 2005;25:858-63.
78. Eiseman E, Bolen JB. Engagement of the highaffinity IgE receptor activates src protein-related tyrosine kinases. Nature. 1992;355:78-80.
79. Wilson BS, Kapp N, Lee RJ, Pfeiffer JR, Martinez AM, Platt Y, Letourneur F, Oliver JM. Distinct functions of the FceR1 γ and β subunits in the control of FcεR1-mediated tyrosine kinase activation and signaling responses in RBL-2H3 mast cells. J Biol Chem. 1995;270:4013-22.
80. Vonakis BM, Gibbons SP, Jr., Rotté MJ, Brothers EA, Kim SC, Chichester K, MacDonald SM. Regulation of rat basophilic leukemia-2H3 mast cell secretion by a constitutive Lyn kinase interaction with the high affinity IgE receptor (FcεRI). J Immunol. 2005;175:4543-54.
81. Benhamou M, Ryba NJP, Kihara H, Nishikata H, Siraganian RP. Protein-tyrosine kinase p72syk in high affinity IgE receptor signaling. Identification as a component of pp72 and association with the receptor γ chain after receptor aggregation. J Biol Chem. 1993;268:23318-24.
82. Shiue L, Green J, Green OM, Karas JL, Morgenstern JP, Ram MK, Taylor MK, Zoller MJ, Zydowsky LD, Bolen JB. Interaction of p72syk with the γ and β subunits of the high-affinity receptor for immunoglobulin E, FcRI. Mol Cell Biol. 1995;15:272-81.
83. Odom S, Gomez G, Kovarova M, Furumoto Y, Ryan JJ, Wright HV, Gonzalez-Espinosa C, Hibbs ML, Harder KW, Rivera J. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med. 2004;199:1491-502.
84. Yamashita Y, Charles N, Furumoto Y, Odom S, Yamashita T, Gilfillan AM, Constant S, Bower MA, Ryan JJ, Rivera J. Cutting edge: genetic variation influences FcεRI-induced mast cell activation and allergic responses. J Immunol. 2007;179:740-743.
85. Parravicini V, Gadina M, Kovarova M, Odom S, Gonzalez-Espinosa C, Furumoto Y, Saitoh S, Samelson LE, O'Shea JJ, Rivera J. Fyn kinase initiates complementary signals required for IgEdependent mast cell degranulation. Nat Immunol. 2002;3:741-48.
86. Choi WS, Hiragun T, Lee JH, Kim YM, Kim H-P, Chahdi A, Her E, Han JH, Beaven MA. Activation of RBL-2H3 mast cells is dependent on tyrosine phosphorylation of phospholipase D2 by Fyn and Fgr. Mol Cell Biol. 2004;24:6980-6992.
87. Lee JH, Kim JW, Kim dK, Kim HS, Park HJ, Park DK, Kim AR, Kim B, Beaven MA, Park KL, Kim YM, Choi WS. The Src family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice. J Immunol. 2011;187:1807-15.
88. Hong H, Kitaura J, Xiao W, Horejsi V, Ra C, Lowell CA, Kawakami Y, Kawakami T. The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn. Blood. 2007;110:2511-19.
89. Iwaki S, Tkaczyk C, Metcalfe DD, Gilfillan AM. Roles of adaptor molecules in mast cell activation. Chem Immunol Allergy. 2005;87:43-58.
90. Alvarez-Errico D, Lessmann E, Rivera J. Adapters in the organization of mast cell signaling. Immunol Rev. 2009;232:195-217.
91. Dráber P, Dráberová L. Lipid rafts in mast cell signaling. Mol Immunol. 2002;38:1247-52.
92. Wilson BS, Pfeiffer JR, Oliver JM. FcεRI signaling observed from the inside of the mast cell membrane. Mol Immunol. 2002;38:1259-68.
93. Sengupta P, Baird B, Holowka D. Lipid rafts, fluid/fluid phase separation, and their relevance to plasma membrane structure and function. Semin Cell Dev Biol. 2007;18:583-90.
94. Silveira E Souza AM, Mazucato VM, Jamur MC, Oliver C. Lipid rafts in mast cell biology. J Lipids. 2011;2011:752906.
95. Saitoh S, Arudchandran R, Manetz TS, Zhang W, Sommers CL, Love PE, Rivera J, Samelson LE. LAT is essential for FcεRI-mediated mast cell activation. Immunity. 2000;12:525-35.
96. Zhu M, Liu Y, Koonpaew S, Granillo O, Zhang W. Positive and negative regulation of FcεRImediated signaling by the adaptor protein LAB/ NTAL. J Exp Med. 2004;200:991-1000.
97. Volná P, Lebduska P, Dráberová L, Simová S, Heneberg P, Boubelik M, Bugajev V, Malissen B, Wilson BS, Horejsi V, Malissen M, Dràber P. Negative regulation of mast cell signaling and function by the adaptor LAB/NTAL. J Exp Med. 2004;200:1001-13.
98. Pivniouk VI, Martin TR, Lu-Kuo JM, Katz HR, Oettgen HC, Geha RS. SLP-76 deficiency impairs signaling via the high-affinity IgE receptor in mast cells. J Clin Invest. 1999;103:1737-43.
99. Wu JN, Jordan MS, Silverman MA, Peterson EJ, Koretzky GA. Differential requirement for adapter proteins Src homology 2 domain-containing leukocyte phosphoprotein of 76 kDa and adhesion-and degranulation-promoting adapter protein in FcεRI signaling and mast cell function. J Immunol. 2004;172:6768-74.
100. Yamasaki S, Takase-Utsugi M, Ishikawa E, Sakuma M, Nishida K, Saito T, Kanagawa O. Selective impairment of FcεRI-mediated allergic reaction in Gads-deficient mice. Int Immunol. 2008;20:1289-97.
101. Barker SA, Caldwell KK, Pfeiffer JR, Wilson BS. Wortmannin-sensitive phosphorylation, translocation, and activation of PLCγ1, but not PLCγ2, in antigen-stimulated RBL-2H3 mast cells. Mol Biol Cell. 1998;9:483-96.
102. Manetz TS, Gonzalez-Espinosa C, Arudchandran R, Xirasagar S, Tybulewicz V, Rivera J. Vav1 regulates phospholipase Cg activation and calcium responses in mast cells. Mol Cell Biol. 2001;21:3763-74.
103. Wilde JI, Watson SP. Regulation of phospholipase C γ isoforms in haematopoietic cells: why one, not the other? Cell Signal. 2001;13:691-701.
104. Tkaczyk C, Beaven MA, Brachman SM, Metcalfe DD, Gilfillan AM. The phospholipase Cγ1-dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem. 2003;278:48474-84.
105. Choi JH, Ryu SH, Suh PG. On/off-regulation of phospholipase C-γ1-mediated signal transduction. Adv Enzyme Regul. 2007;47:104-16.
106. 2+2independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells: reconstitution of secretory responses with Ca21 and purified isozymes in washed permeabilized cells. J Biol Chem. 1993;268:1749-56.
107. 2+ signaling with particular focus on mast cells. Crit Rev Immunol. 2009;29:155-86.
108. 2+ store to the plasma membrane. Nature. 2005;437:902-5.
109. Salido GM, Jardin I, Rosado JA. The TRPC ion channels: association with Orai1 and STIM1 proteins and participation in capacitative and non-capacitative calcium entry. Adv Exp Med Biol. 2011;704:413-33.
110. 2+ signaling systems. Trends Cell Biol. 2011;21:202-11.
111. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, Hogan PG, Lewis RS, Daly M, Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature. 2006;441:179-85.
112. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. Nature. 2006;443:230-233.
113. 2+ entry. Science. 2006;312:1220-1223.
114. 2+, and degranulation in a rat mast cell line. J Immunol. 2008;180:2233-39.
115. 2+ responses in mast cells. J Immunol. 2009;183:6478-88.
116. Di Capite JL, Bates GJ, Parekh AB. Mast cell CRAC channel as a novel therapeutic target in allergy. Curr Opin Allergy Clin Immunol. 2011;11:33-38.
117. 2+ signaling in mast cells: potential targets for treatment of mast cell-related diseases? Adv Exp Med Biol. 2011;716:62-90.
118. Chang EY, Szallasi Z, Acs P, Raizada V, Wolfe PC, Fewtrell C, Blumberg PM, Rivera J. Functional effects of overexpression of protein kinase C-α,-β,-δ,-ε, and-η in the mast cell line RBL-2H3. J Immunol. 1997;159:2624-32.
119. 2+ and protein kinase C signaling for histamine and sulfidoleukotrienes released from human cultured mast cells. Biochem Biophys Res Commun. 1999;257:895-900.
120. Nechushtan H, Leitges M, Cohen C, Kay G, Razin E. Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cb. Blood. 2000;95:1752-57.
121. Nechushtan H, Razin E. Studies of different aspects of the role of protein kinase C in mast cells. Int Arch Allergy Immunol. 2001;124:130-132.
122. Li G, Lucas JJ, Gelfand EW. Protein kinase Ca, bI, and bII isozymes regulate cytokine production in mast cells through MEKK2/ERK5-dependent and-independent pathways. Cell Immunol. 2005;238:10-18.
123. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, Fox R, Bruce I, Walker C, Sawyer C, Okkenhaug K, Finan P, Vanhaesebroeck B. Essential role for the p110d phosphoinositide 3-kinase in the allergic response. Nature. 2004;431:1007-11.
124. Yu M, Lowell CA, Neel BG, Gu H. Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcεRI. J Immunol. 2006;176:2421-29.
125. Kim MS, Radinger M, Gilfillan AM. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 2008;29:493-501.
126. Hata D, Kitaura J, Hartman SE, Kawakami Y, Yokota T, Kawakami T. Bruton's tyrosine kinasemediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway. J Biol Chem. 1998;273:10979-87.
127. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD, Gilfillan AM. The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. J Immunol. 2008;181:7706-12.
128. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON, Kawakami T. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol. 2000;165:1210-1219.
129. 2+ signaling in mast cells by tyrosine-phosphorylated and unphosphorylated non-T cell activation linker. J Immunol. 2007;179:5169-80.
130. Iwaki S, Spicka J, Tkaczyk C, Jensen BM, Furumoto Y, Charles N, Kovarova M, Rivera J, Horejsi V, Metcalfe DD, Gilfillan AM. Kit-and FcεRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/ LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal. 2008;20:195-205.
131. Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson LE, Satterthwaite AB, Nahm DH, Metcalfe DD, Gilfillan AM. NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcεRI aggregation. Blood. 2004;104:207-14.
132. Kambayashi T, Okumura M, Baker RG, Hsu CJ, Baumgart T, Zhang W, Koretzky GA. Independent and cooperative roles of adaptor molecules in proximal signaling during FcεRImediated mast cell activation. Mol Cell Biol. 2010;30:4188-96.
133. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 pathway in mast cells. J Immunol. 2008;180:4586-95.
134. 2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem. 2011;286:391-402.
135. Rådinger M, Kuehn HS, Kim MS, Metcalfe DD, Gilfillan AM. Glycogen synthase kinase 3b activation is a prerequisite signal for cytokine production and chemotaxis in human mast cells. J Immunol. 2010;184:564-72.
136. Novotny V, Prieschl EE, Csonga R, Fabjani G, Baumruker T. Nrf1 in a complex with fosB, c-jun, junD and ATF2 forms the AP1 component at the TNFa promoter in stimulated mast cells. Nucleic Acids Res. 1998;26:5480-5485.
137. Hutchinson LE, McCloskey MA. FcεRImediated induction of nuclear factor of activated T-cells. J Biol Chem. 1995;270:16333-38.
138. Turner H, Cantrell DA. Distinct Ras effector pathways are involved in FcεRI regulation of the transcriptional activity of Elk-1 and NFAT in mast cells. J Exp Med. 1997;185:43-53.
139. Hock MB, Brown MA. Nuclear factor of activated T cells 2 transactivation in mast cells: a novel isoform-specific transactivation domain confers unique FcεRI responsiveness. J Biol Chem. 2003;278:26695-703.
140. Monticelli S, Solymar DC, Rao A. Role of NFAT proteins in IL13 gene transcription in mast cells. J Biol Chem. 2004;279:36210-36218.
141. Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Tertilt C, Bopp T, Heib V, Becker M, Taube C, Schild H, Schmitt E, Stassen M. Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol. 2006;177:6667-74.
142. 2+ entry and NFAT activation in lymphocytes. Cell Calcium. 2007;42:145-56.
143. Marquardt DL, Walker LL. Dependence of mast cell IgE-mediated cytokine production on NF-kB activity. J Allergy Clin Immunol. 2000;105:500-505.
144. Pelletier C, Varin-Blank N, Rivera J, Iannascoli B, Marchand F, David B, Weyer A, Blank U. FcεRImediated induction of TNF-α gene expression in the RBL-2H3 mast cell line: regulation by a novel NF-kB-like nuclear binding complex. J Immunol. 1998;161:4768-76.
145. Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. Mast cell homeostasis and the JAKSTAT pathway. Genes Immun. 2010;11:599-608.
146. Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD, Ryan JJ. Stat5 expression is required for IgE-mediated mast cell function. J Immunol. 2006;177:3421-26.
147. Pullen NA, Barnstein BO, Falanga YT, Wang Z, Suzuki R, Lama Tamang TD, Khurana MC, Harry EA, Rivera J, Draber P, Bunting KD, Mizuno K, Wilson BS, Ryan JJ. A novel mechanism for FcεRI-mediated signal transducer and activator of transcription 5 (Stat5) tyrosine phosphorylation and the selective influence of Stat5B over mast cell cytokine production. J Biol Chem. 2011;in press.
148. Malaviya R, Uckun FM. Role of STAT6 in IgE receptor/FcεRI-mediated late phase allergic responses of mast cells. J Immunol. 2002;168:421-26.
149. Ryan JJ, DeSimone S, Klisch G, Shelburne C, McReynolds LJ, Han K, Kovacs R, Mirmonsef P, Huff TF. IL-4 inhibits mouse mast cell FcεRI expression through a STAT6-dependent mechanism. J Immunol. 1998;161:6915-23.
150. Kennedy NS, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, Ford J, Conrad D, Watowich S, Moralle MR, Kepley CL, Murray PJ, Ryan JJ. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol. 2008;180:2848-54.
151. Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD. IgG-dependent activation of human mast cells following up-regulation of FcεRI by IFN-a. Eur J Immunol. 2001;31:3298-307.
152. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/ leukemia; activation following aggregation of FcεRI or FcεRI. Leuk Res. 2003;27:677-82.
153. Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD. Activation of human mast cells through the high affinity IgG receptor. Mol Immunol. 2002;38:1289-93.
154. Okayama Y, Tkaczyk C, Metcalfe DD, Gilfillan AM. Comparison of FcεRI-and FcεRI-mediated degranulation and TNF-α synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for FcεRI-induced degranulation. Eur J Immunol. 2003;33:1450-1459.
155. Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcεRI: additive effects of C3a. Clin Immunol. 2004;110:172-80.
156. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF. Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J Immunol. 1992;148:868-71.
157. Katz HR, Lobell RB. Expression and function of FcγR in mouse mast cells. Int Arch Allergy Immunol. 1995;107:76-78.
158. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med. 1999;189:1573-79.
159. Chong HJ, Andrew BL, Bailey DP, Wright H, Ramirez C, Gharse A, Oskeritzian C, Xia HZ, Zhu J, Paul WE, Kepley C, Schwartz LB, Ryan JJ. IL-4 selectively enhances FcεRIII expression and signaling on mouse mast cells. Cell Immunol. 2003;224:65-73.
160. Dastych J, Hardison MC, Metcalfe DD. Aggregation of low affinity IgG receptors induces mast cell adherence to fibronectin. Requirement for the common FcRγ-chain. J Immunol. 1997;158:1803-9.
161. Fong DC, Malbec O, Arock M, Cambier JC, Fridman WH, Daëron M. Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated FcεRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett. 1996;54:83-91.
162. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fcg-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med. 2002;8:518-21.
163. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-74.
164. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23:16-43.
165. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol. 2008;154:1572-82.
166. Shivakrupa R, Linnekin D. Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. Cell Signal. 2005;17:103-9.
167. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006;533:327-40.
168. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992;79:958-63.
169. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994;153:3717-23.
170. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006;34:97-115.
171. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell. 1990;63:185-94.
172. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345-64.
173. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20:21-39.
174. Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV, Martin FH, Williams DA. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci U S A. 1992;89:7350-7354.
175. Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med. 1992;175:237-44.
176. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ. Differential release of mast cell interleukin-6 via c-kit. Blood. 1997;89:2654-63.
177. Ishizuka T, Kawasome H, Terada N, Takeda K, Gerwins P, Keller GM, Johnson GL, Gelfand EW. Stem cell factor augments FcgRI-mediated TNF-α production and stimulates MAP kinases via a different pathway in MC/9 mast cells. J Immunol. 1998;161:3624-30.
178. Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. J Immunol. 2000;164:43-48.
179. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood. 2004;104:2410-2417.
180. 2b receptor. Biochem Pharmacol. 2002;64:317-25.
181. Moon TC, Murakami M, Ashraf MD, Kudo I, Chang HW. Regulation of cyclooxygenase-2 and endogenous cytokine expression by bacterial lipopolysaccharide that acts in synergy with c-kit ligand and FcεRI crosslinking in cultured mast cells. Cell Immunol. 1998;185:146-52.
182. Fehrenbach K, Lessmann E, Zorn CN, Kuhny M, Grochowy G, Krystal G, Leitges M, Huber M. Steel factor enhances supraoptimal antigeninduced IL-6 production from mast cells via activation of protein kinase C-b. J Immunol. 2009;182:7897-905.
183. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110:2331-33.
184. Ando A, Martin TR, Galli SJ. Effects of chronic treatment with the c-kit ligand, stem cell factor, on immunoglobulin E-dependent anaphylaxis in mice. Genetically mast cell-deficient Sl/Sld mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses. J Clin Invest. 1993;92:1639-49.
185. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol. 2001;167:2250-2256.
186. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol. 2001;70:977-84.
187. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002;109:1351-59.
188. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170:1625-29.
189. Varadaradjalou S, Feger F, Thieblemont N, Hamouda NB, Pleau JM, Dy M, Arock M. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. 2003;33:899-906.
190. Okumura S, Kashiwakura J, Tomita H, Matsumoto K, Nakajima T, Saito H, Okayama Y. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcεRI. Blood. 2003;102:2547-54.
191. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol. 2004;4:787-99.
192. Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. J Allergy Clin Immunol. 2006;118:837-43.
193. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.
194. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051-54.
195. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, Nakae S. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971-78.
196. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, Okayama Y, Akira S, Saito H, Galli SJ, Nakae S. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals. J Leukoc Biol. 2007;82:1481-90.
197. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40:216-25.
198. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104:282-87.
199. Pushparaj PN, Tay HK, H'ng SC, Ptman N, Xu D, McKenzie A, Liew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock. Proc Nat Acad Sci USA. 2009;106:9773-78.
200. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105:10913-18.
201. Liew FY, Pitman NI, McInnes IB. Diseaseassociated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103-10.
202. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. 2010;40:200-208.
203. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010;107:4448-53.
204. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, Melendez AJ, Liew FY. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010;184:2620-2626.
205. Hsu C-L, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;5:e11944.
206. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20-38.
207. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179:2551-55.
208. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104:18660-18665.
209. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42:358-64.
210. Gadina M, Jefferies CA. IL-33: a sheep in wolf's clothing? Sci STKE. 2007;2007:e31.
211. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-40.
212. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-IkB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999;398:252-56.
213. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol. 2002;22:7158-67.
214. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668-81.
215. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood. 2008;113:1526-34.
216. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88-and p38a-dependent pathway. J Leukoc Biol. 2009;86:769-78.
217. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019-30.
218. Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981-89.
219. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res. 2010;59:207-18.
220. Carneiro LA, Magalhaes JG, Tattoli I, Philpott DJ, Travassos LH. Nod-like proteins in inflammation and disease. J Pathol. 2008;214:136-48.
221. Haidl ID, McAlpine SM, Marshall JS. Enhancement of mast cell IL-6 production by combined Toll-like and nucleotidebinding oligomerization domain-like receptor activation. Int Arch Allergy Immunol. 2011;154:227-35.
222. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6:9-20.
223. Sahar S, Reddy MA, Wong C, Meng L, Wang M, Natarajan R. Cooperation of SRC-1 and p300 with NF-kB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007;27:1528-34.
224. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808:1290-1308.
225. Verzijl D, Ijzerman AP. Functional selectivity of adenosine receptor ligands. Purinergic Signal. 2011;7:171-92.
226. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 2011;63:1-34.
227. Rizzolio F, La Montagna R., Tuccinardi T, Russo G, Caputi M, Giordano A. Adenosine receptor ligands in clinical trials. Curr Top Med Chem. 2010;10:1036-45.
228. Polosa R, Holgate ST. Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation. Curr Drug Targets. 2006;7:699-706.
229. Fozard JR. The case for a role for adenosine in asthma: almost convincing? Curr Opin Pharmacol. 2003;3:264-69.
230. Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, Borea PA. The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev. 2010;10:61-64.
231. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol. 2005;86:1-41.
232. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis. 1988;138:1143-51.
233. Heaney LG, Cross LJ, Ennis M. Histamine release from bronchoalveolar lavage cells from asthmatic subjects after allergen challenge and relationship to the late asthmatic response. Clin Exp Allergy. 1998;28:196-204.
234. 2-purinoceptor mediated mechanism. Biochem Pharmacol. 1984;33:3847-52.
235. 3R is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993;268:16887-90.
236. Marquardt DL, Walker LL, Heinemann S. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol. 1994;152:4508-15.
237. 3 receptor. J Immunol. 2003;171:338-45.
238. 3 receptor activation in rats. Eur J Pharmacol. 1996;298:293-97.
239. 3 adenosine receptor. Circ Res. 1996;78:627-34.
240. 3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood. 1996;88:3569-74.
241. 3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol. 2004;173:1380-1389.
242. Versluis M, Postma DS, Timens W, Hylkema MN. Effects of IL-4 and IL-13 on adenosine receptor expression and responsiveness of the human mast cell line 1. Int Immunopharmacol. 2008;8:866-73.
243. Collado-Escobar D, Cunha-Melo JR, Beaven MA. Treatment with dexamethasone downregulates IgE-receptor mediated signals and up-regulates adenosine-receptor mediated signals in a rat mast cell (RBL-2H3) line. J Immunol. 1990;144:244-50.
244. 3 adenosine receptors in rat basophilic leukemia (RBL-2H3) cells. J Immunol. 1995;154:5436-43.
245. 2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol. 2004;172:7726-33.
246. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann MP. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity. 2002;16:441-51.
247. Lionetti FJ, Hunt SM, Lin PS, Kurtz SR, Valeri CR. Preservation of human granulocytes. II. Characteristics of granulocytes obtained by counterflow centrifugation. Transfusion. 1977;17:465-472:465-72.
248. Humes JL, Bonney RJ, Pelus L, Dahlgren ME, Sadowski SJ, Kuehl FA, Jr., Davies P. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature. 1977;269:149-51.
249. 2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 b-treated human synovial fibroblasts. J Biol Chem. 2001;276:31720-31.
250. 2 on interleukin-1 b-induced cyclooxygenase-2 expression in human airway smooth-muscle cells. Am J Respir Crit Care Med. 2000;162:2272-77.
251. 2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol. 2002;169:4586-93.
252. 2 that differentially modulate activation responses. Blood. 2006;107:3243-50.
253. 2-responder and non-responder phenotypes in human mast cell populations: "All or nothing" enhancement of antigen-dependent mediator release. Immunol Lett. 2011;PMID 21798286.
254. 2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. 2006;147:707-13.
255. Kuehn HS, Beaven MA, Ma HT, Kim MS, Metcalfe DD, Gilfillan AM. Synergistic activation of phospholipases Cγ and Cβ: a novel mechanism for PI3K-independent enhancement of FcεRI-induced mast cell mediator release. Cell Signal. 2008;20:625-36.
256. 3-dependent mechanism. J Immunol. 2000;165:6545-52.
257. 3 receptors. Allergy. 2006;61:503-6.
258. Kuehn HS, Rådinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, Metcalfe DD, Gilfillan AM. Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci. 2010;123:2576-85.
259. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11:403-15.
260. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S. Transactivation of sphingosine-1-phosphate receptors by FcεRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med. 2004;199:959-70.
261. Olivera A, Urtz N, Mizugishi K, Yamashita Y, Gilfillan AM, Furumoto Y, Gu H, Proia RL, Baumruker T, Rivera J. IgE-dependent activation of spingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. J Biol Chem. 2006;281:2515-25.
262. Olivera A, Rivera J. An emerging role for the lipid mediator sphingosine-1-phosphate in mast cell effector function and allergic disease. Adv Exp Med Biol. 2011;716:123-42.
263. 2 receptor in allergen-induced, mast cell-dependent contraction of rat lung parenchymal strips. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:303-9.
264. Choi OH, Kim JH, Kinet JP. Calcium mobilization via the sphingosine kinase in signalling by the FcεRI antigen receptor. Nature. 1996;380:634-36.
265. 2+ mobilization in RBL-2H3 cells: role of I(1,4,5)P3 and S1P and necessity of I(1,4,5)P3 production. Cell Calcium. 2005;38:581-92.
266. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753-63.
267. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood. 2008;111:4193-200.
268. Oskeritzian CA, Price MM, Hait NC, Kapitonov D, Falanga YT, Morales JK, Ryan JJ, Milstien S, Spiegel S. Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. J Exp Med. 2010;207:465-74.
269. Olivera A, Mizugishi K, Tikhonova A, Ciaccia L, Odom S, Proia RL, Rivera J. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity. 2007;26:287-97.
270. Olivera A, Eisner C, Kitamura Y, Dillahunt S, Allende L, Tuymetova G, Watford W, Meylan F, Diesner SC, Li L, Schnermann J, Proia RL, Rivera J. Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice. J Clin Invest. 2010;120:1429-40.
271. Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcεRI-mediated mast cell activation. Immunol Lett. 2007;113:59-69.
272. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, Brown JM, Bruening S, Toth M, Metcalfe DD. 5-Hydroxytryptamine induces mast cell adhesion and migration. J Immunol. 2006;177:6422-32.
273. Papadopoulos EJ, Fitzhugh DJ, Tkaczyk C, Gilfillan AM, Sassetti C, Metcalfe DD, Hwang ST. Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur J Immunol. 2000;30:2355-61.
274. Romagnani P, de PA, Beltrame C, Annunziato F, Dente V, Maggi E, Romagnani S, Marone G. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol. 1999;155:1195-204.
275. Taub D, Dastych J, Inamura N, Upton J, Kelvin D, Metcalfe D, Oppenheim J. Bone marrow-derived murine mast cells migrate, but do not degranulate, in response to chemokines. J Immunol. 1995;154:2393-402.
276. Ahamed J, Venkatesha RT, Thangam EB, Ali H. C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J Immunol. 2004;172:6961-68.
277. Thangam EB, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP, Amrani Y, Panettieri RA, Jr., Ali H. Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. FASEB J. 2005;19:798-800.
278. Kashem SW, Subramanian H, Collington SJ, Magotti P, Lambris JD, Ali H. G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2. Eur J Pharmacol. 2011;PMID 21741965.
279. Bienenstock J, MacQueen G, Sestini P, Marshall JS, Stead RH, Perdue MH. Mast cell/nerve interactions in vitro and in vivo. Am Rev Respir Dis. 1991;143:S55-S58.
280. Pundir P, Kulka M. The role of G protein-coupled receptors in mast cell activation by antimicrobial peptides: is there a connection? Immunol Cell Biol. 2010;88:632-40.
281. Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci. 1990;11:358-62.
282. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 2008;123:398-410.
283. Fewtrell CM, Foreman JC, Jordan CC, Oehme P, Renner H, Stewart JM. The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol (Lond). 1982;330:393-411.
284. Devillier P, Drapeau G, Renoux M, Regoli D. Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. Eur J Pharmacol. 1989;168:53-60.
285. Ogawa K, Nabe T, Yamamura H, Kohno S. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats. Eur J Pharmacol. 1999;374:285-91.
286. Erjavec F, Lembeck F, Florjanc-Irman T, Skofitsch G, Donnerer J, Saria A, Holzer P. Release of histamine by substance P. Naunyn Schmiedebergs Arch Pharmacol. 1981;317:67-70.
287. Mousli M, Bronner C, Bueb JL, Tschirhart E, Gies JP, Landry Y. Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther. 1989;250:329-35.
288. Okayama Y, Ono Y, Nakazawa T, Church MK, Mori M. Human skin mast cells produce TNF-α by substance P. Int Arch Allergy Immunol. 1998;117 Suppl 1:48-51.
289. van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol. 2003;171:2074-79.
290. Lowman MA, Benyon RC, Church MK. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol. 1988;95:121-30.
291. Grundemar L, Hakanson R. Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells. Br J Pharmacol. 1991;104:776-78.
292. De Jonge F, De Laet A, Van Nassauw L, Brown JK, Miller HR, van Bogaert PP, Timmermans JP, Kroese ABA. In vitro activation of murine DRG neurons by CGRP-mediated mucosal mast cell degranulation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G178-G191.
293. Suzuki R, Furuno T, Teshima R, Nakanishi M. Bi-directional relationship of in vitro mast cell-nerve communication observed by confocal laser scanning microscopy. Biol Pharm Bull. 2001;24:291-94.
294. Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, Bienenstock J. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol. 1999;163:2410-2415.
295. Nordlind K, Theodorsson E. Plasma concentrations and urinary excretion of regulatory peptides in patients with urticaria pigmentosa. Ups J Med Sci. 1993;98:169-78.
296. Wesley JR, Vinik AI, O'Dorisio TM, Glaser B, Fink A. A new syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide. Gastroenterology. 1982;82:963-67.
297. Johansson O. Morphological characterization of the somatostatin-immunoreactive dendritic skin cells in urticaria pigmentosa patients by computerized image analysis. Scand J Immunol. 1985;21:431-39.
298. Maintz L, Wardelmann E, Walgenbach K, Fimmers R, Bieber T, Raap U, Novak N. Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis. Allergy. 2011;66:862-69.
299. El Karim IA, Linden GJ, Orr DF, Lundy FT. Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol. 2008;200:11-16.
300. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170:2274-78.
301. Di Nardo A, Yamasaki K, Dorschner RA, Lai Y, Gallo RL. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J Immunol. 2008;180:7565-73.
302. von Kockritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norrby-Teglund A, Rohde M, Medina E. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood. 2008;111:3070-80.
303. Yount NY, Bayer AS, Xiong YQ, Yeaman MR. Advances in antimicrobial peptide immunobiology. Biopolymers. 2006;84:435-58.
304. Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J. Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human a-defensin family. J Immunol. 2007;179:3958-65.
305. Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J. b-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol. 2007;37:2474-86.
306. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol. 1999;163:947-53.
307. 2 production from mast cells. Eur J Immunol. 2001;31:1066-75.
308. Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, Saito H, Nagaoka I, Ikeda S, Okumura K, Ogawa H. Antimicrobial peptides human b-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol. 2007;37:434-44.
309. Yoshioka M, Fukuishi N, Kubo Y, Yamanobe H, Ohsaki K, Kawasoe Y, Murata M, Ishizumi A, Nishii Y, Matsui N, Akagi M. Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol Pharm Bull. 2008;31:212-16.
310. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K, Kajiwara N, Saito H, Nagaoka I, Ogawa H, Okumura K. Antimicrobial peptides human b-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol. 2010;184:3526-34.
311. Chen X, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, Ogawa H. Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J Dermatol Sci. 2006;43:63-66.
312. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human b-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol. 2002;14:421-26.
313. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, Nagaoka I. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2002;106:20-26.
314. Aung G, Niyonsaba F, Ushio H, Kajiwara N, Saito H, Ikeda S, Ogawa H, Okumura K. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology. 2011;132:527-39.
315. Mousli M, Hugli TE, Landry Y, Bronner C. Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology. 1994;27:1-11.
316. Ferry X, Brehin S, Kamel R, Landry Y. G proteindependent activation of mast cell by peptides and basic secretagogues. Peptides. 2002;23:1507-15.
317. Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol. 2006;30:19-23.
318. 2+-mobilizing receptor-mediated biosignaling system. J Biol Chem. 1985;260:3584-93.
319. 2+ fluxes and histamine release in rat mast cells stimulated with compound 48/80. Agents Actions. 1984;15:279-84.
320. 2 in rat peritoneal mast cells: roles of cytosolic calcium and protein tyrosine kinases. Biochim Biophys Acta. 1995;1265:79-88.
321. i3. Science. 1993;262:1569-72.
322. Shefler I, Taube Z, Medalia O, Sagi-Eisenberg R. Basic secretagogues activate protein tyrosine phosphorylation and release of arachidonic acid in mast cells via a novel protein kinase C and phosphatidylinositol 3-kinase-dependent mechanism. Eur J Immunol. 1998;28:3468-78.
323. Byrne RD, Rosivatz E, Parsons M, Larijani B, Parker PJ, Ng T, Woscholski R. Differential activation of the PI 3-kinase effectors AKT/PKB and p70 S6 kinase by compound 48/80 is mediated by PKCa. Cell Signal. 2007;19:321-29.
324. Chahdi A, Fraundorfer PF, Beaven MA. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J Phamacol Exp Ther. 2000;292:122-30.
325. 2 in cell membranes. J Biol Chem. 2003;278:12039-45.
326. Peng Z, Beaven MA. An essential role for phospholipase D in the activation of protein kinase C and degranulation in mast cells. J Immunol. 2005;174:5201-8.
327. Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, Lee HH, Ryu SD, von GS, Bickel CA, Hudson SA, MacGlashan DW, Jr., Bochner BS. Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol. 2008;121:499-505.
328. Guthmann MD, Tal M, Pecht I. A secretion inhibitory signal transduction molecule on mast cells is another C-type lectin. Proc Natl Acad Sci U S A. 1995;92:9397-401.
329. Udell CM, Samayawardhena LA, Kawakami Y, Kawakami T, Craig AW. Fer and Fps/Fes participate in a Lyn-dependent pathway from FcεRI to platelet-endothelial cell adhesion molecule 1 to limit mast cell activation. J Biol Chem. 2006;281:20949-57.
330. Katz HR, Austen KF. A newly recognized pathway for the negative regulation of mast cell-dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. J Immunol. 1997;158:5065-70.
331. Uehara T, Blery M, Kang DW, Chen CC, Ho LH, Gartland GL, Liu FT, Vivier E, Cooper MD, Kubagawa H. Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J Clin Invest. 2001;108:1041-50.
332. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173:6786-93.
333. Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol. 2005;175:7989-95.
334. Kataoka TR, Kumanogoh A, Bandara G, Metcalfe DD, Gilfillan AM. CD72 negatively regulates KIT-mediated responses in human mast cells. J Immunol. 2010;184:2468-75.
335. Enerbäck L. Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties. Acta Pathol Microbiol Scand. 1966;66:303-12.
336. Enerbäck L. Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand. 1966;66:289-302.
337. Enerbäck L, Norrby K. The mast cells. Curr Top Pathol. 1989;79:169-204.
338. Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George TI, Sotlar K, Sperr WR, Horny HP. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010;23:369-78.
339. Kitamura Y, Kasugai T, Arizono N, Matsuda H. Development of mast cells and basophils: processes and regulation mechanisms. Am J Med Sci. 1993;306:185-91.
340. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007;217:304-28.
341. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy. 2008;38:4-18.
342. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams DE. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell. 1990;63:235-43.
343. Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T, Asai H, Yonezawa T, Kitamura Y, Galli SJ. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med. 1985;162:1025-43.
344. Levi-Schaffer F, Austen KF, Gravallese PM, Stevens RL. Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A. 1986;83:6485-88 (erratum in 83:7805, 1986).
345. Razin E, Ihle JN, Seldin D, Mencia-Huerta JM, Katz HR, LeBlanc PA, Hein A, Caulfield JP, Austen KF, Stevens RL. Interleukin 3: a differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol. 1984;132:1479-86.
346. Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A. 1991;88:6382-86.
347. Dayton ET, Pharr P, Ogawa M, Serafin WE, Austen KF, Levi-Schaffer F, Stevens RL. 3T3 fibroblasts induce cloned interleukin 3-dependent mouse mast cells to resemble connective tissue mast cells in granular constituency. Proc Natl Acad Sci U S A. 1988;85:569-72.
348. Gilead L, Bibi O, Razin E. Fibroblasts induce heparin synthesis in chondroitin sulfate E containing human bone marrow-derived mast cells. Blood. 1990;76:1188-95.
349. Swieter M, Hamawy MM, Siraganian RP, Mergenhagen SE. Mast cells and their microenvironment: the influence of fibronectin and fibroblasts on the functional repertoire of rat basophilic leukemia cells. J Periodontol. 1993;64:492-96.
350. Karimi K, Redegeld FA, Heijdra B, Nijkamp FP. Stem cell factor and interleukin-4 induce murine bone marrow cells to develop into mast cells with connective tissue type characteristics in vitro. Exp Hematol. 1999;27:654-62.
351. Friend DS, Ghildyal N, Gurish MF, Hunt J, Hu X, Austen KF, Stevens RL. Reversible expression of tryptases and chymases in the jejunal mast cells of mice infected with Trichinella spiralis. J Immunol. 1998;160:5537-45.
352. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: Recent Advances. Annu Rev Immunol. 2005;23:749-86.
353. Kalesnikoff J, Galli SJ. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol Allergy. 2010;95:45-66.
354. Befus AD, Pearce FL, Goodacre R, Bienenstock J. Unique functional characteristics of mucosal mast cells. Adv Exp Med Biol. 1982;149:521-27.
355. Lowman MA, Rees PH, Benyon RC, Church MK. Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgEdependent and nonimmunologic stimuli. J Allergy Clin Immunol. 1988;81:590-597.
356. Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, Kiev J, Schwartz LB. Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J Allergy Clin Immunol. 2005;115:1162-68.
357. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93-104.
358. Burton OT, Oettgen HC. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol Rev. 2011;242:128-43.
359. Weller CL, Collington SJ, Williams T, Lamb JR. Mast cells in health and disease. Clin Sci (Lond). 2011;120:473-84.
360. Sayed BA, Christy A, Quirion MR, Brown MA. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008;26:705-39.
361. Dimson OG, Giudice GJ, Fu CL, Van den Bergh F, Warren SJ, Janson MM, Fairley JA. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120:784-88.
362. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol. 2007;127:2605-11.
363. Leighty L, Li N, Diaz LA, Liu Z. Experimental models for the autoimmune and inflammatory blistering disease, bullous pemphigoid. Arch Dermatol Res. 2007;299:417-22.
364. Lin L, Bankaitis E, Heimbach L, Li N, Abrink M, Pejler G, An L, Diaz LA, Werb Z, Liu Z. Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid. J Biol Chem. 2011;286:37358-67.
365. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005;12:167-81.
366. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev. 2007;217:19-37.
367. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297:1689-92.
368. Corr M, Crain B. The role of FcgR signaling in the K/B x N serum transfer model of arthritis. J Immunol. 2002;169:6604-9.
369. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, Benoist C, Mathis D, Lee DM. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A. 2007;104:2325-30.
370. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature. 2002;420:875-78.
371. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity. 1996;5:387-90.
372. Brenner T, Soffer D, Shalit M, Levi-Schaffer F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci. 1994;122:210-213.
373. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol. 1995;37:63-66.
374. Walker ME, Hatfield JK, Brown MA. New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? Biochim Biophys Acta. 2011;1822:57-65.
375. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med. 2000;191:813-22.
376. Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol. 2002;38:1373-78.
377. Sayed BA, Christy AL, Walker ME, Brown MA. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment? J Immunol. 2010;184:6891-900.
378. Nakamura Y, Kambe N, Saito M, Nishikomori R, Kim YG, Murakami M, Núñez G, Matsue H. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med. 2009;206:1037-46.
379. Tsai M, Grimbaldeston MA, Yu M, Tam SY, Galli SJ. Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in vivo. Chem Immunol Allergy. 2005;87:179-97.
380. Katz HR, Austen KF. Mast cell deficiency, a game of kit and mouse. Immunity. 2011;35:668-70.
381. W-sh mice does not impair antibody-mediated arthritis. J Exp Med. 2007;204:2797-802.
382. Feyerabnd TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, Radermacher P, Möller P, Benoiste C, Mathis D, Fehling HJ, Rodewald H-R. Cremediated cell ablation contests mast cell contribution in models of antibody-and T cell-mediated autoimmunity. Immunity. 2011;35:832-44.
383. Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Köhler A, Peschke K, Vöhringer D, Waskow C, Krieg T, Müller W, Waisman A, Hartmann K, Gunzer M, Roers A. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011;34:973-84.
384. Woodbury RG, Miller HR, Huntley JF, Newlands GF, Palliser AC, Wakelin D. Mucosal mast cells are functionally active during spontaneous expulsion of intestinal nematode infections in rat. Nature. 1984;312:450-452.
385. Nawa Y, Kiyota M, Korenaga M, Kotani M. Defective protective capacity of W/Wv mice against Strongyloides ratti infection and its reconstitution with bone marrow cells. Parasite Immunol. 1985;7:429-38.
386. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature. 1996;381:77-80.
387. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381:75-77.
388. Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol. 2008;181:5598-605.
389. Shelburne CP, Nakano H, St John AL, Chan C, McLachlan JB, Gunn MD, Staats HF, Abraham SN. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe. 2009;6:331-42.
390. Wershil BK, Castagliuolo I, Pothoulakis C. Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology. 1998;114:956-64.
391. Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, Maurer M. Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol. 2007;170:1910-16.
392. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol. 2000;67:841-46.
393. Castleman WL, Sorkness RL, Lemanske RF, Jr., McAllister PK. Viral bronchiolitis during early life induces increased numbers of bronchiolar mast cells and airway hyperresponsiveness. Am J Pathol. 1990;137:821-31.
394. Choi SY, Huang P, Jenkins GM, Chan DC, Schiller J, Frohman MA. A common lipid links Mfn-mediated mitochondrial fusion and SNARE-regulated exocytosis. Nat Cell Biol. 2006;8:1255-62.
395. Sugiyama K. Histamine release from rat mast cells induced by Sendai virus. Nature. 1977;270:614-15.
396. Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, Bulfone-Paus S. TLR3-induced activation of mast cells modulates CD81 T-cell recruitment. Blood. 2005;106:978-87.
397. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by doublestranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol. 2004;114:174-82.
398. Urb M, Pouliot P, Gravelat FN, Olivier M, Sheppard DC. Aspergillus fumigatus induces immunoglobulin E-independent mast cell degranulation. J Infect Dis. 2009;200:464-72.
399. Larsen FO, Clementsen P, Hansen M, Maltbaek N, Gravesen S, Skov PS, Norn S. The indoor microfungus Trichoderma viride potentiates histamine release from human bronchoalveolar cells. APMIS. 1996;104:673-79.
400. Edelson BT, Stricker TP, Li Z, Dickeson SK, Shepherd VL, Santoro SA, Zutter MM. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood. 2006;107:143-50.
401. Kolaczkowska E, Seljelid R, Plytycz B. Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast cell-deficient WBB6F1 mice. J Leukoc Biol. 2001;69:33-42.
402. Edelson BT, Li Z, Pappan LK, Zutter MM. Mast cell-mediated inflammatory responses require the a2b 1 integrin. Blood. 2004;103:2214-20.
403. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6:135-42.
404. Wang HW, Tedla N, Lloyd AR, Wakefield D, McNeil PH. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest. 1998;102:1617-26.
405. Tedla N, Wang HW, McNeil HP, Di GN, Hampartzoumian T, Wakefield D, Lloyd A. Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)-1a and MIP-1b. J Immunol. 1998;161:5663-72.
406. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, Gunn MD, Abraham SN. Mast cellderived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol. 2003;4:1199-205.
407. Maurer M, Lopez Kostka S, Siebenhaar F, Moelle K, Metz M, Knop J, von Stebut E. Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J. 2006;20:2460-67.
408. Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity. 2004;20:381-92.
409. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol. 2006;176:4102-12.
410. Jawdat DM, Albert EJ, Rowden G, Haidl ID, Marshall JS. IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol. 2004;173:5275-82.
411. Jawdat DM, Rowden G, Marshall JS. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol. 2006;177:1755-62.
412. Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M, Bopp T, Taube C, Schild H, Schmitt E, Stassen M. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood. 2007;110:946-53.
413. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006;176:2238-48.
414. McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon R, Staats HF, Abraham SN. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med. 2008;14:536-41.
415. Pulendran B, Ono SJ. A shot in the arm for mast cells. Nat Med. 2008;14:489-90.
416. Heib V, Becker M, Taube C, Stassen M. Advances in the understanding of mast cell function. Br J Haematol. 2008;142:683-94.
417. + T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev. 2001;182:164-79.
418. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997-1002.
419. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771-81.
420. Crivellato E, Beltrami CA, Mallardi F, Ribatti D. The mast cell: an active participant or an innocent bystander? Histol Histopathol. 2004;19:259-70.
421. Nakayama T, Yao L, Tosato G. Mast cellderived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest. 2004;114:1317-25.
422. Kneilling M, Hultner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Rocken M. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum. 2007;56:1806-16.
423. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13:1211-18.
424. Clinton M, Long WF, Williamson FB, Duncan JI, Thompson WD. Effect of the mast cell activator compound 48/80 and heparin on angiogenesis in the chick chorioallantoic membrane. Int J Microcirc Clin Exp. 1988;7:315-26.
425. Detoraki A, Staiano RI, Granata F, Giannattasio G, Prevete N, de Paulis A., Ribatti D, Genovese A, Triggiani M, Marone G. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol. 2009;123:1142-49.
426. Ribatti D, Crivellato E, Candussio L, Nico B, Vacca A, Roncali L, Dammacco F. Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. Clin Exp Allergy. 2001;31:602-8.
427. Norrby K, Jakobsson A, Sorbo J. Mast-cellmediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52:195-206.
428. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618-31.
429. Liu J, Zhang Y, Zhao J, Yang Z, Li D, Katirai F, Huang B. Mast cell: insight into remodeling a tumor microenvironment. Cancer Metastasis Rev. 2011;30:177-84.
430. Shin K, Nigrovic PA, Crish J, Boilard E, McNeil HP, Larabee KS, Adachi R, Gurish MF, Gobezie R, Stevens RL, Lee DM. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 2009;182:647-56.
431. Kahlson G, Nilsson K, Rosengren E, Zelderfeldt B. Wound healing as dependent on rate of histamine formation. Lancet. 1960;276:230-234.
432. Artuc M, Steckelings UM, Henz BM. Mast cellfibroblast interactions: human mast cells as source and inducers of fibroblast and epithelial growth factors. J Invest Dermatol. 2002;118:391-95.
433. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382-97.
434. Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-68.
435. Iba Y, Shibata A, Kato M, Masukawa T. Possible involvement of mast cells in collagen remodeling in the late phase of cutaneous wound healing in mice. Int Immunopharmacol. 2004;4:1873-80.
436. Shiota N, Nishikori Y, Kakizoe E, Shimoura K, Niibayashi T, Shimbori C, Tanaka T, Okunishi H. Pathophysiological role of skin mast cells in wound healing after scald injury: study with mast cell-deficient W/Wv mice. Int Arch Allergy Immunol. 2010;151:80-88.
437. Westphal E. Über Mastzellen. 1891;17-41.
438. Theoharides TC, Conti P. Mast cells: the JEKYL and HYDE of tumor growth. Trends Immunol. 2004;25:235-41.
439. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9:1215-23.
440. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer. 1999;2:26-32.
441. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000;88:2686-92.
442. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, Roncali L, Dammacco F. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer. 2003;39:666-74.
443. W-v mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest. 2005;85:388-96.
444. v mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer. 1988;42:48-52.
445. Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A., Santoro M, Marone G. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29:6203-15.
446. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A. 2007;104:19977-82.
447. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008;454:436-44.
448. Aoki M, Pawankar R, Niimi Y, Kawana S. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol. 2003;130:216-23.
449. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res. 1997;17:1541-49.
450. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249-57.
451. Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate. 2009;69:976-81.
452. Hedström G, Berglund M, Molin D, Fischer M, Nilsson G, Thunberg U, Book M, Sundström C, Rosenquist R, Roos G, Erlanson M, Amini RM, Enblad G. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol. 2007;138:68-71.
453. Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis. 2008;29:880-886.
454. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol. 2010;185:7067-76.
455. Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tete S, Mastrangelo F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC. Role of mast cells in tumor growth. Ann Clin Lab Sci. 2007;37:315-22.